Zimmer Biomet Holdings Inc

ZBH remains in a Stage 2 advancing regime with a valid higher-high/higher-low sequence. Despite a Bullish Exhaustion pattern and rejection at the 200-day MA, price holds above rising 9- and 21-period EMAs and the 50 DMA. Medium-term directional bias stays bullish, and the current pullback into the EMA zone offers a selective entry. Short-term conditions favor buying this shallow retracement.

• ↑Q1 2026 adjusted EPS rose 15% YoY to $2.09; revenue $2.087B (+9.3%).
• ↑Organic constant-currency sales up 2.9%, top of 2026 guidance range.
• ↓Paragon 28 integration poses execution risk; Q1 operating margins down.